Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effectiveness of ECP in Diffuse Cutaneous Systemic Sclerosis
NCT04986605Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methoxsalen in diffuse cutaneous systemic sclerosis (dcSSc). Primary endpoint: modified Rodnan Skin Score at 48 weeks. Started May 2025; status: recruiting.
02
Drugs
methoxsalen
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT04986605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04986605.